Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)
Year: 2020
Type: conference-abstract
Source: Cancer Research
Authors: Ian E Krop, Cristina Saura, Toshinari Yamashita, Yeon Hee Park, Sung-Bae Kim, Kenji Tamura, Fabrice André, Hiroji Iwata, Yoshinori Ito, Junji Tsurutani, Joohyuk Sohn, Neelima Denduluri, Christophe Perrin, Kenjiro Aogi, Eriko Tokunaga, Seock-Ah Im, Keun Seok Lee, Sara Hurvitz, Javier Cortes, Caleb Lee, Shuquan Chen, Lin Zhang, Javad Shahidi, Antoine Yver, Shanu Modi
Institutions: Dana-Farber Cancer Institute, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Kanagawa Cancer Center, Samsung Medical Center, Asan Medical Center, National Cancer Centre Japan, Université Paris-Sud, Institut Gustave Roussy, Aichi Cancer Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, SHOWA Medical University, Kindai University, Yonsei University Health System, Yonsei Cancer Hospital, Virginia Cancer Specialists, The US Oncology Network, Centre Eugène Marquis, Shikoku Cancer Center, National Hospital Organization Kyushu Cancer Center, Seoul National University Hospital, National Cancer Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Daiichi Sankyo (United States), Memorial Sloan Kettering Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3006600886